Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date. What about interaction between abacavir + tenofovir+ videx?
Marty Markowitz, M. D.
Clinical Director
Staff Investigator, Aaron Diamond AIDS Research Center
Associate Professor, Rockefeller University
When coadministering tenofovir [Viread] and ddI [Videx] the dose of ddI [Videx] should be reduced to 250 mg qd. Tenofovir (TDF) dosing should be 300 mg daily, the usual dosage.
The combination you write of is a triple nucleoside regimen; to date once daily triple nucleoside therapy with ABC [abacavir=Ziagen] + 3TC [lamivudine=Epivir] +TDF [Viread], or ddI [Videx], 3TC [lamivudine=Epivir] and TDF [Viread] have resulted in high numbers of early virologic failures....So a more important consideration might be whether or not one should be on this regimen at all.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, Roche and Trimeris, the National Library of Medicine, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.